Linda-Gail Bekker, who helped prove the drug Lenacapavir’s effectiveness, tells The Independent that $40 doses bring hope – ...

Low- and middle-income countries will be able to purchase an effective preventative at a reduced price. The arrangements may ...

This antiretroviral has shown unprecedented results in HIV prevention, requiring only two injections per year. Its ...

Scientists say the drug stops the virus from replicating inside cells. The landmark deal to provide cheaper antiretroviral ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

A twice-yearly injection described as the most promising HIV prevention tool in decades is poised to reach millions more ...

Bengaluru: Indian drugmakers Dr Reddy's Laboratories and Hetero Labs said on Wednesday that they will sell generic versions ...

Hyderabad-based drugmakers Dr. Reddy’s Laboratories and Hetero Labs have signed separate agreements that will make their generic version of Gilead Sciences’ HIV prevention drug Lenacapavir available ...

Two partnerships will provide millions of people access to what is widely described as the most effective HIV prevention drug ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

A new HIV prevention drug, Lenacapavir, will be made available at a significantly reduced cost in over 100 low-income countries by 2027.

Generics of Gilead Sciences' twice-yearly HIV pre-exposure prophylaxis (PrEP) Yeztugo (lenacapavir) are on the horizon, with ...